TY - JOUR JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW SP - 157 LP - 157 VL - 24 IS - 135 AU - A.B. Cortot Y1 - 2015/03/01 UR - http://err.ersjournals.com/content/24/135/157.abstract N2 - Fighting Lung Cancer through the HER Family of Surface Receptors Edited by Diego Márquez-Medina Published by Nova Science Publishers Inc. Pages: 311. Price: £123.00. ISBN: 978-1-63321-092-9 Treatment of lung cancer has evolved considerably over the past few years thanks to a better understanding of the molecular mechanisms involved in lung carcinogenesis, and the development of new drugs that are able to inhibit specific key signalling pathways within the cancer cell. The best illustration of this (r)evolution is the story of epidermal growth factor receptor (EGFR or HER1) inhibitors, which have become the cornerstone for the treatment of EGFR-mutated lung cancers. These drugs were initially thought to yield modest benefit in the overall population of nonsmall cell lung cancer (NSCLC) patients, but the discovery of EGFR mutations revealed a unique model of oncogene addiction in lung cancer associated with exquisite sensitivity to EGFR inhibition. However, many questions remain on the management and treatment of NSCLC, especially regarding EGFR and other HER family members. How should we screen for EGFR mutations? Can we use other biomarkers for predicting efficacy of HER inhibitors? Why don't all the patients with EGFR-mutated NSCLC respond to EGFR tyrosine kinase inhibitors (TKIs)? How should we manage acquired resistance to EGFR TKIs? ER -